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ABSTRACT 
Current serological diagnostics of the zoonotic disease brucellosis, caused by the 
intracellular, facultative bacterial pathogen Brucella, is primarily limited to humoral 
antibodies against the O-side chain of the lipopolysaccharide. This limitation can result in 
false positives due to cross reactivity with other gram negative bacteria. Previous attempts to 
identify other molecular markers for diagnostic purposed haven’t resulted in sensitive and 
specific antigens. In the current study, we employed a new method for discovering novel 
Brucella proteins that induce humoral responses in cattle. We developed a phage display 
library that expresses 56 amino acid long Brucella peptides. Screening the library with sera 
from B. abortus RB51 infected cattle demonstrated that it identified antigenic peptides of 
Brucella. Fifty peptides demonstrated greater humoral responses at 30 days after RB51 
infection as compared to sera obtained prior to vaccination. Peptides identified in the study 
could be beneficial as potential targets for novel Brucella diagnostics.  
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CHAPTER 1.    INTRODUCTION 
Brucellosis is a global zoonotic disease caused by bacterial species of the genus 
Brucella. The disease has a large agricultural impact in developing countries by causing 
abortions and sterility in livestock such as cattle, pigs, goats and sheep. Quick and reliable 
diagnostics of Brucella infection is critical to limit the spread of the pathogen. Current 
diagnostic techniques are based on the O side chain of the LPS. This poses a problem of 
cross reactivity with other gram negative bacteria, such as Yersinia species, and leads to false 
positives. It is our goal to create a diagnostic test specific to Brucella species so as to 
eliminate this problem. Our approach is to identify antigenic proteins that are Brucella 
specific, so they can be used to test an animal’s humoral response to the pathogen. To 
identify these proteins, we created a T7 phage display library that expresses 56 amino acid 
peptides of B. suis, B. melitensis and B. abortus. Together, the phage library contains over 
35,000 unique peptide sequences. This was used to screen sera from B. abortus strain RB51 
vaccinated cattle for antibody responses. Phage that expressed antigenic peptides were 
collected for DNA extraction and sequencing. This data demonstrates proteins which 
stimulate humoral responses and novel candidates for development of a new diagnostic tests.  
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CHAPTER 2.    LITERATURE REVIEW 
Brucella 
The genus Brucella encompasses a number of species of facultative, Gram negative 
bacteria with high genetic homology with preference for localization with intracellular 
compartments of phagocytic, reticuloendothelial, and specialized epithelial cells. Genome 
sequences of the six classical species of Brucella (B. abortus, B. suis, B. melitensis, B. ovis, 
B. canis, and B. neotomae) display an average of greater than 94% identity at the nucleotide 
level (Chain et al., 2005; Vizcaino et al., 2000). When compared to other bacteria, the 
classical Brucella species are most closely related to plant pathogens in the Ochrabactrum 
genus (Paulsen et al., 2002, Bavishi, Abhishek et al., 2010). In recent years, new species of 
Brucella have been identified including B. microti in common voles (Microtus arvalis), B. 
ceti and B. pinnipedalis in marine mammals, B. inoptinota from a human breast implant and 
Australian rodents, and new proposed strains from baboons (Papio spp.) and African 
bullfrogs (Pyxicephalus edulis) (Olsen and Palmer, 2014).   
Brucella species are named based on their preferred natural host but most members of 
the genus can infect and cause clinical disease in multiple hosts. The genus is primarily 
known for causing infertility and reproductive losses in mammalian hosts. In particular, 
clinical effects include late term abortions in females, and orchitis, epididymitis, and 
inflammation of accessory sex glands in males (Olsen and Palmer, 2014). However, Brucella 
can localize in almost any tissue with clinical signs dependent on the site of infection.  For 
example, localization in osteoarticular tissues can result in arthritis, bone proliferation, and 
lameness, and B. suis has been found to cause paralysis in swine if the localization occurs 
within the vertebral column (Baldi et al., 2013; Olsen Swine Brucellosis chapter). Many of 
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the species in the genus are zoonotic with brucellosis in humans primarily associated with 
infections with B. abortus, B. melitensis, and B. suis. However, B. canis and marine isolates 
can also cause human infection (Olsen and Palmer, 2014). Human infection is generally 
considered to be a chronic disease, with recurring “flu-like” symptoms. However, severe 
clinical manifestations can occur including endocarditis, abortion, and neurobrucellosis 
(Baldi, 2013). Although classical species in the genus do not exist as commensals, and are 
not found free-living in the environment (Roop et al., 2003), the newly identified Brucella 
species may demonstrate differences as environmental persistence could play a role in their 
pathogenesis and transmission. However, for Brucella species of importance in domestic 
livestock, maintenance of brucellosis in an animal or human population requires continual 
infection in reservoir hosts. 
Most wild-type field strains of B. abortus, B. suis, and B. melitensis are smooth 
strains because they express an O-polysaccharide (O side-chain) as part of their 
lipopolysaccharide (LPS). The O side-chain is an immunodominant antigen of Brucella and, 
in general, induces humoral responses within one week of infection in domestic livestock 
hosts. In addition, live vaccine strains (B. abortus strain 19 and B. melitensis strain Rev1) are 
smooth and express the O side-chain on their LPS.  
Brucella species (B. abortus, B. melitensis, and B. suis) are subdivided into biovaars 
based on biochemical, phenotypic, and antigenic properties. Biotyping has been used for 
epidemiologic purposes but is somewhat subjective due to measurement of subtle differences 
including requirements for higher CO2 tensions for growth, production of hydrogen sulphide, 
growth on media containing dyes (thionin or basic fuchsin), and agglutination with 
monospecific A and M antisera (Alton et al., 1990).   
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The genomes of the classical Brucella strains generally have two circular 
chromosomes encoding approximately 3.2 kb with two replicons. Genomic studies have 
predicted between 3,355 and 3,408 protein encoding genes in B. melitensis (Tan et al., 2015), 
3,296 in a B. abortus biovar 1 (Halling et al., 2005), and 3,366 in B. suis biovar 1 (Di et al., 
2016).  Currently, genome assemblies are available in GenBank for B. abortus (n = 210), B. 
melitensis (n = 189), B. suis (n = 62), and B. canis (n = 22) with fewer assemblies available 
for other Brucella spp. Bacteriophages have been isolated from Brucella strains, but plasmids 
have not (Corbel, 1987). Brucellae utilize multiple mechanisms to protect against DNA 
mutations resulting in the high genetic homology across the genus. Although PCR and 
variable nuclear tandem repeat-based assays allow differentiation of species and biovars, the 
stability of the brucellae genomes do not allow use of molecular assays, such as restriction 
fragment length polymorphism, to assess genetic relationships between isolates. 
 
Brucellosis in the United States and Regulatory Programs  
Prior to the 1960’s, brucellosis was endemic within domestic livestock in the United 
States causing thousands of clinical cases of human brucellosis most likely by direct contact 
or by consumption of unpasteurized milk products. Beginning as a disease control program 
during a drought in the 1930’s, brucellosis has been a regulatory disease in the United States 
for decades with a formal eradication program initiated in the 1950s (Ragan, 2002).  In 1954, 
Congress formally delegated funds for the eradication program primarily because of its 
public health benefits. Multiple studies have demonstrated that the most economical method 
to prevent human brucellosis is to address the disease in animal reservoirs (Roth et al., 2003; 
Bernues et al., 1997).  
5  
The regulatory program is based on serologic testing to identify infected livestock, 
trace backs of positive responses to the herd(s) of origin, and quarantine and testing to 
eliminate brucellosis from infected herds. It has been estimated that between 1934 and 2000, 
approximately $11 billion in federal, state, and private funds were invested to eradicate 
brucellosis from domestic livestock in the United States (Olsen et al., 2015). In addition to 
reducing human disease, the eradication program in domestic livestock dramatically reduced 
the economic cost of brucellosis for livestock producers and was estimated to have prevented 
$18.3 billion dollars in losses in the United States.   
Currently, B. abortus has been essentially eradicated from the United States except 
for wild populations of bison (approximately 5000) and elk (approximately 25,000 on winter 
feed grounds annually; Cotterill et al., 2017) in areas surrounding Yellowstone National 
Park.  Over 25 cattle herds have been infected with B. abortus since 2002 with elk being the 
most likely source of disease transmission. In a similar manner, millions of feral swine 
inhabit the United States particularly in the southeast. Serologic and culture methods have 
indicated that brucellosis is endemic in feral swine populations (Pederson et al., 2017) and 
human infection by transmission from feral swine is not uncommon (Brown et al., 2018). 
Feral swine have frequently transmitted swine brucellosis to cattle and domestic swine, with 
Texas once reporting more than 24 B. suis infected cattle in a 2 year period. 
 
Brucella Serologic Diagnostic Tests 
The major antigen involved in the serological response against in vivo infection with 
smooth strains of Brucella is the lipopolysaccharide (S-LPS). Essentially all conventional 
brucellosis surveillance tests (card, standard tube agglutination, rivanol, complement 
fixation, fluorescence polarization, PCFIA, ELISAs, etc.) are based on detection of 
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antibodies to the O-side-chain on the LPS or the components of the LPS (Bundle and 
McGiven, 2017). Although the LPS antigen can also be subdivided into A dominant (B. 
abortus) and M dominant (B. melitensis) subtypes, the majority of standard brucellosis 
serologic tests use the LPS O side-chain from B. abortus as antigen, and were initially 
developed for detection of B. abortus infections in cattle. 
Under current regulations, both screening (high sensitivity, lower specificity; ex card 
test) and confirmatory (high specificity, lower sensitivity; ex complement fixation or 
fluorescence polarization) tests are used for serologic testing of livestock (Ducrotoy et al., 
2016). This approach minimizes false positive responses and enhances specificity. Estimates 
of test sensitivity and specificity can vary dependent upon the test and the degree of infection 
in the animal population, as test performance is often calculated by comparison to the “gold 
standard” of bacterial isolation. This may explain the great variation in estimates of 
sensitivity and specificity for these tests as reported in published studies. It is important to 
understand that an animal testing positive for antibodies to the O-side-chain induces 
regulatory actions, including repeat testing, trace back and testing of the herd of origin, and 
possible quarantine of the originating herd (Ragan, 2002).   
However, a number of bacteria such as Yersinia enterocolitica O:9, Escherichia coli 
O157:H7, Salmonella spp., and others have a similar lipopolysaccharide structure to smooth 
strains of Brucella that can cause false positive responses on brucellosis surveillance tests 
(Dieste-Perez et al., 2015; Bundle, Cherwonogrodzky et al., 1989). Brucella vaccine strains 
can also induce humoral responses that react on conventional serologic tests. These false 
positive responses cannot be differentiated from infection with field strains using current 
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serologic tests and confound interpretation of diagnostic results particularly at the current 
time when prevalence of brucellosis is very low within U.S. domestic livestock populations. 
Because of the similarity of the smooth LPS across Brucella species, it is also not 
possible to use serologic tests to determine which strain of Brucella is causing positive 
serologic responses. For example, this can be important in instances where cattle are infected 
with B. suis. Brucella suis is not a regulatory disease in cattle, but infection with B. abortus 
does requires regulatory actions (and federal financial resources). This is the reason why it is 
important for regulatory personnel to determine the etiology of infection under field 
conditions. 
Also, current brucellosis diagnostic tests cannot identify infections caused by rough 
strains of Brucella, which express a truncated form of LPS on their surface. One example is 
B. canis, which not only causes clinical disease in dogs but can also cause brucellosis in 
humans. Another rough Brucella, B. ovis, is a regulatory pathogen in sheep for which there is 
currently not a diagnostic test with high sensitivity and specificity. Identification of protein 
antigens which induce humoral responses could be beneficial for diagnosis of rough strains 
in addition to serving as companion test for currently available serologic tests. 
For many reasons, new diagnostic antigens need to be identified that can be used in 
diagnostic tests to resolve false positive responses caused by cross-reacting bacteria, allow 
serologic identification of animals infected with rough strains of Brucella, and serve as 
complementary tests for identification of domestic livestock infected with virulent field 
strains. In addition, as purification of LPS from Brucella is time consuming and can lead to 
variability between extraction lots, development of recombinant proteins as diagnostic 
antigens could provide antigens of higher quality with economic advantages. 
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Brucella Antigens That Induce Humoral Response 
Despite decades of work to identify Brucella immunogenic antigens that would lead 
to serologic tests with greater sensitivity and specificity, little progress has been made. Many 
studies have focused on utilization of various extraction methods (phenol-water, acetic acid 
hydrolysis, hot water-alcohol precipitation, gel filtration chromatography, trichloroacetic 
acid, and ether-chloroform-phenol) to extract Brucella LPS or polysaccharides for use as 
antigens in serologic assays (Godfroid et al., 2015). Others have modified this approach by 
preparing synthetic glycoproteins under the hypothesis that chemical structures of the LPS 
could be modified to reduce cross-reactivity (Bundle and Ciocchini et al., 2014, Cortina et 
al., 2016, McGiven et al., 2015). Currently these LPS extraction methods and synthetic LPS 
antigens have not resulted in significant improvements in specificity of serologic tests. In 
addition, they do not t allow differentiation of humoral responses caused by smooth vaccine 
strains or allow identification of the Brucella species causing infection. 
Another approach has been to use a hot saline extraction technique to prepare soluble 
periplasmic proteins of Brucella for use in serologic assays (Ismael et al., 2016). Others have 
focused on outer-membrane proteins (OMP) such as OMP2a, OMP10, OMP19, OMP28 
OMP31 (Mohammadi and Golchin, 2018, Im et al., 2018, Pathak et al., 2017; Simborio et al., 
2015; Twari et al., 2013). Studies have evaluated OMP28 for its diagnostic value in humans 
(Lindler et al., 1996; Karothia et al., 2013), cattle (Lim et al., 2012), and cattle, sheep, goats, 
and dogs (Chaudhuri et al., 2010). All studies reported high sensitivity and specificity in sets 
of test sera but no further work has been reported. Another study found that combining 
recombinant OMP10, OMP19, and OMP28 proteins demonstrated high sensitivity for 
serologic diagnosis of brucellosis (Simborio et al., 2015). However, it should be noted that 
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some control samples in this study demonstrated high reactivity to the recombinant antigens 
(Simborio et al., 2015). It should be noted that, in general, use of outer membrane proteins in 
serodiagnostics do not appear to result in significant increases in sensitivity and specificity as 
compared to currently available serologic tests (Lettesson et al., 1997). Although not 
implemented for diagnostic use at the current time, they might be useful for ruling out 
possible false positive responses caused by cross-reacting bacteria. However, one report 
concluded that no single serological test or antigen combination, including outer membrane 
protein complexes, demonstrates 100% sensitivity and specificity simultaneously for 
eliminating false-positive responses in cattle (Munoz et al., 2005). 
 Several other protein antigens have also been evaluated for use in brucellosis 
serologic tests. In humans, cytoplasmic, outer membrane, and inner membrane antigenic 
fractions were demonstrated to be immunogenic (Goldbaum et al., 1991). Further work found 
that cytoplasmic proteins of B. abortus that have been depleted of LPS were useful in 
serologic detection of inactive human brucellosis (Goldbaum et al., 1992) and diagnosis of B. 
canis (Baldi et al., 1994). Cytosolic protein preparations and a recombinant periplasmic 
protein of B. abortus (BP26) have been evaluated in cattle but did not demonstrate acceptable 
sensitivity/specificity ratios (Munoz et al., 2005). In regards to other single immunogenic 
proteins of Brucella, limited data reported that an 18-kDa cytoplasmic protein was 
immunogenic in humans and cattle (Goldbaum et al., 1993). Also, a cell surface protein 
associated with a type IV secretion system (VirB12) had high sensitivity and specificity in 
detection of brucellosis in humans (Mirkalantari et al., 2017). A recombinant bacterioferritin 
of B. abortus demonstrated 85% sensitivity and 93% specificity in cattle when compared to 
standard tube agglutination test responses. As with outer-membrane proteins, overall data 
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suggests that these antigens may prove useful in supplemental tests for current diagnostics 
but probably would not be suitable as “stand alone” diagnostic tests. As some of the antigens 
were first characterized many years previously, the lack of implementation of diagnostic tests 
is probably indicative of their value for use under field conditions. 
Multiple other studies have used two dimensional gel electrophoresis and Western 
blotting including sera from Brucella-infected animals and in attempts to identify 
immunogenic peptides of Brucella (Kim et al., 2014, Zygmunt et al., 1994; Ko et al., 2012; 
Wareth et al., 2016; Lee et al., 2015). Some of the studies included Western blotting with 
sera from Yersinia-infected and E. coli-infected animals to eliminate cross-reactive peptides 
(Kim et al., 2014; Ko et al.,2012) The results were highly variable with only two proteins, 
Cu/Zn superoxide dismutase and DnaK, a heat shock protein, showing up as antigenic in 
more than one study. Some of the work suggests that immunogenicity of individual proteins 
may vary by host species (Wareth et al., 2016).  
 
Phage Immunoprecipitation Sequencing (PhIP-Seq) 
PhIP-Seq is a technique that allows for the high-throughput analysis of antibody-
repertoire binding specificities for a specific pathogen or set of pathogens (Larman et al., 
2011). In this approach, each open reading frame is divided into a series of 100 to 300 base 
pair oligonucleotides with overriding ends that allow expression of linear protein epitopes 
(approximately 33 to 90 amino acids) within a bacteriophage, a virus that only infects 
bacteria. After expression of the oligo library in a bacteriophage, linear proteins (encoded by 
the oligos) to which antibodies react are subsequently precipitated using serum from infected 
subjects and compared to the repertoire when sera from control subjects is screened.  
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This technique was initially reported for characterization of autoantigens in 
autoimmune disease. By generating a synthetic representation of the complete human 
proteome (> 413,000 peptides representing all open reading frames), the library was screened 
for autoantibodies using cerebral spinal fluid of patients with paraneoplastic neurologic 
syndromes (Larman et al., 2011). Enriched phage populations were identified using high 
throughput DNA sequencing resulting in identification of known and novel autoantigens. The 
work was expanded to screen the expression library with serum from patients with type 1 
diabetes, serum and central spinal fluid from patients with multiple sclerosis, and serum and 
synovial fluid from patients with rheumatoid arthritis to identify disease specific autoantigens 
that may contribute to the pathogenesis of these diseases. Responses were compared to 
similar screenings from serum, CSF, or synovial fluid from healthy donors. This work 
resulted in the identification of 6 autoantigens that might be involved in the pathogenesis of 
type 1 diabetes, 16 for rheumatoid arthritis, and 8 for multiple sclerosis (Larman et al., 2013). 
This phage display method has also been applied to viruses as with the creation of a 
human viral peptidome containing 206 human viruses and over 1000 viral strains (Larman et 
al., 2015). With this phage library, a patient can be screened for a complete viral infection 
history based on circulating antibodies in their blood. This could be used as a diagnostic tool 
for exposure to viruses instead of testing for each virus separately and allows estimation of 
the timeline when a patient was infected with each virus based on the quantification step 
through high-throughput sequencing. 
This approach has several advantages over previously used techniques for the 
identification of antigens. This all-inclusive approach provides a non-biased proteomic 
analysis, with the ability to cover all ORF. Additionally, it does not rely on protein isolation 
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and extraction methods, which can lead to loss protein targets due to insolubility, stability or 
low expression. Furthermore, this method provides a streamlined, multiplex protocol 
requiring only one enrichment step for the identification of a large repertoire of antigens. 
Lastly, it allows quantification of each peptide’s antibody-binding enrichment by use of high 
throughput sequencing. Negative aspects of the procedure are that expressed peptides may 
lack many of the conformational epitopes present on full-length proteins, and post-
translational modifications and di-sulfide bonds will be absent. It can be argued that PhIP-
Seq is currently the most comprehensive approach for identification of antigenic proteins 
within a targeted genomic sequence.  
Use of a phage library to screen an intracellular pathogen like Brucella is attractive 
because it may allow identification of antigenic epitopes that have not been previously 
identified through other methods. By screening linear peptides of approximately 57 amino 
acids, it may allow identification of epitopes that were previously masked due to tertiary 
conformations of native proteins, or denaturing conditions used in gel electrophoresis. 
Although longer linear peptides might contain greater secondary structure, they may contain 
more mutations that would reduce the overall quality of the library (Mohan et al., 2018). 
Shorter linear epitopes are also more attractive as diagnostic antigens in that they may be 
easier to express than the entire protein. Another strategy would be to create an oligo 
containing a combination of antigenic linear epitopes or even smaller antigenic fragments. 
This could allow preparation of a diagnostic antigen that includes multiple epitopes across 
multiple proteins that may enhance the sensitivity and specificity of the assay. 
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CHAPTER 3.    METHODS 
Oligonucleotide Library Design 
Whole proteomes of three Brucella species, B. abortus 2308 (NC_007618.1, 
NC_007624.1), B. suis 1330 (NC_004310.3, NC_004311.2), and B. melitensis 16M 
(NC_003317.1, NC_003318.1), were obtained from NCBI and run through BLASTp against 
the RefSeq prokaryote reference database. Individual proteins from all Brucella species were 
evaluated to identify similar protein sequences from distantly related organisms. Proteins 
with strong sequence similarity (≥ 80%) to organisms outside the Brucellaceae and 
Rhizobiaceae families were excluded from the library. 
Protein sequences were reverse translated using E. coli codon preferences and then 
reverse transcribed into complementary DNA (cDNA) sequences. Each unique cDNA 
sequence was divided into 168 oligonucleotide fragments starting at the first base of the 
sequence with a new fragment starting after every 84 bases so that adjacent oligo sequences 
overlapped by 84 bases. The last oligo for a protein was made up of the last 168 nucleotides 
of the DNA sequence. Common leader sequences were added to the 5` 
(AGGAATTCATCGCTGCGT) and 3` (CAGGGAAGCAAGCTTGAA) ends of each unique 
oligo, providing primer annealing sites and restriction enzyme binding sites (EcoR1 and 
HindIII, respectively) to allow for efficient cloning into the commercial T7 bacteriophage 
vector.  
Redundant oligo sequences shared between the three Brucella species were deleted 
such that only one replicate of each oligo was present within the library. After preparation of 
sequences to include in the library, the oligonucleotides were synthesized by a commercial 
source (Agilent Technologies).  
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E. coli culture 
An Escherichia coli BLT5403 glycerol stock was provided in the T7Select Cloning 
Kit (Novagen) and stored at -80 ºC. The stock culture was streaked for isolated colonies onto 
lysogeny broth (LB) plates supplemented with 50 µg/ml carbenicillin and incubated 
overnight at 37 ºC. A single colony was taken from the plate to inoculate a flask of LBcarb and 
incubated overnight at 37 ºC with shaking. To obtain mid-log culture, 1 ml of the overnight 
liquid culture of E. coli was inoculated into 50 ml of LBcarb and incubated at 37 ºC with 
shaking until an OD600 value of 0.8 was reached. The mid-log culture was then stored at 4 ºC 
until further use. 
 
Phage Library Preparation 
The lyophilized oligonucleotide library was initially resuspended in deionized (DI) 
water to a concentration of 0.5 pmol/µl. After further dilution to 25 fmol/µl in DI water, 
oligos were PCR amplified in a 50µl volume consisting of 2.5 units TaKaRa Ex Taq® DNA 
Polymerase, 1x TaKaRa Ex Taq DNA Polymerase Buffer, 1mM dNTPs, 1µM oligoampL 
primer, 1µM oligoampR primer and 500 pM oligo template with the following thermocycler 
protocol (Table 1). PCR products were purified using a commercial kit (MinElute, Qiagen), 
quantified on a fluorometer (Qubit 2.0), and checked for purity via spectrophotometer 
(Nanodrop 2000).   
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Table 1  Thermocycler protocol for Agilent oligonucleotide PCR 
Step Temperature (ºC) Time (MM:SS) 
1 96 00:30 
2 96 00:35 
3 50 00:35 
4 72 00:30 
5 (go to step 2) x3 
6 72 05:00 
7 96 00:30 
8 96 00:30 
9 70 00:35 
10 72 00:30 
11 (go to step 8) x10 
12 72 05:00 
13 4 ∞ 
 
Preparation of T7 bacteriophage expressing the oligo library was performed using a 
commercial kit T7Select 10-3 Cloning Kit (Novagen), according to manufacturer’s 
recommendations. Briefly, purified DNA amplicons were double digested using HindIII-
HF® and EcoRI-HF® in CutSmart® Buffer (New England Biolabs) leaving a 5’ –AATT 
sticky end on top strands and a 5’ –AGCT sticky end on bottom strands to allow for in-frame 
cloning.  After purification of amplicons using a commercial kit (MinElute, Qiagen), and 
reassessment of concentration, digested DNA was ligated to EcoR I/HindIII vector arms to 
allow directional cloning. Ligated DNA was mixed with T7 Packaging Extracts to assemble 
T7 phage particles containing Brucella DNA.   
Assembled phage were quantified by mixing serially diluted (10-5 – 10-11) phage with 
mid-log phase E. coli BLT5403 and LB top agar followed by overlay onto LB plates. After 
overnight growth at room temperature, plaques were counted to determine plaque forming 
units per milliliter (pfu/ml) in the phage library stock solution. To amplify the titer of the 
phage stock, E. coli BLT5403 were grown in a shaking incubator at 37 ºC and phage were 
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added at mid-log phase. After incubation to a time point when lysed cell debris was visible, 
the suspension was centrifuged at 10,000 x g for 10 minutes, and the phage-containing 
supernatant was collected. The phage concentration in the amplified phage stock was 
quantified again as described previously.  
 
Animal vaccinations 
Holstein steers, 6-8 months old, were housed in field barns at the National Animal 
Disease Centers (NADC) in Ames, IA. All experiments were approved by the NADC 
Institutional Animal Care and Use Committee (IACUC). Steers were vaccinated 
subcutaneously (SQ) with 1010 colony-forming units (CFU) of a commercial RB51 vaccine 
(Colorado Serum Company) in the cervical region.  Blood was collected via venipuncture at 
4-week intervals to track humoral responses.  
 
RB51-specific IgG responses 
Blood was collected into clot tubes and serum was obtained via centrifugation. Serum 
samples were aliquoted and stored at -20 ºC until analysis. Humoral IgG responses to RB51 
were assessed via enzyme-linked immunosorbent assay (ELISA) as previously described 
(Olsen et al., 2009) with some modifications.  Briefly, 96-flat bottom plates were coated with 
1 x 108 CFU of formalin-killed RB51 diluted in coating buffer (carbonate-bicarbonate buffer, 
pH 9.6) and incubated overnight at 4 C. Blocking of wells was performed using SuperBlock 
(ThermoFisher) in accordance with manufacturer’s recommendations. After a wash step with 
wash buffer (PBS with 0.05% Tween 20), serum samples were added in triplicate to wells at 
a dilution of 1:1600 and incubated at RT for 2 hours. Plates were washed and then incubated 
with peroxidase-conjugated rabbit anti-bovine IgG (H+L) (Jackson Immunoresearch 
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laboratories, West Grove, PA; 1:25,000) for 1 hour at RT. Following a wash step, plates were 
developed using the TMB Microwell Peroxidase Substrate System (ThermoFisher) in 
accordance with manufacturer recommendations.  After incubation, the reaction was stopped 
with 0.18 M solution of sulfuric acid and absorbance was measured at 450 nm using a plate 
reader.  
Concentration of IgG within sera were quantified using Bovine IgG ELISA 
Quantitation Set (Bethyl Laboratories Inc) quantitation kit, according to manufacturer’s 
recommendation. Time points with peak humoral responses to RB51 and total IgG 
concentration were used to determine which samples to use for screening the phage library. 
Selected serum samples were diluted with DI water to 2 µg/µl IgG. 
 
Phage Library Immunoprecipitation and Propagation 
Microfuge tubes were incubated in blocking buffer (50 mM Tris-HCl, 150 mM NaCl, 
0.5% Tween 20, 3% IgG-free BSA, pH 7.6) overnight at 4 ºC with rotation. After removal of 
coating buffer, 1 ml M9LB medium + 0.1% Tween, 5 µl phage stock (4 x 107 pfu/µl) and 2 
µl serum (2 µg IgG/µl) were added to each tube (in quadruplicate) and incubated at room 
temperature (RT) with rotation. After a 4 hr incubation, 30 µl of a 1:1 mix of Protein G and 
Protein A coated magnetic beads (Dynabeads, Invitrogen) were added to each tube. Tubes 
were incubated for 2 hr at RT with rotation. Tubes were then placed on a magnetic rack to 
capture the beads. The supernatant was removed and the beads were resuspended in 
immunoprecipitation (IP) wash buffer (150 mM NaCl, 50 mM Tris-HCl, 0.1% NP-40, pH 
7.5). Beads were washed 2 times, transferred to a new microfuge tube and washed an 
additional 2 times. After the last wash, captured beads were resuspended in 50 µl of 
denaturing buffer (TBS + 1% SDS) to release the phage from bound antibodies and incubated 
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at RT for 10 minutes, with gentle mixing every couple of minutes. Tubes were then placed 
back on the magnetic rack to capture the beads, and the supernatant, containing 
immunoprecipitated phage, was removed and transferred into glass culture tubes containing 
10 ml mid-log E. coli BLT5403 to propagate recovered phages. Cultures were incubated 
overnight, with shaking at RT. The next day, 1 ml of each culture was added to a microfuge 
tube and centrifuged for 5 minutes at 20,000 x g. The supernatant containing propagated 
phages was aspirated and placed into a clean microfuge tube and stored at 4 ºC. Two more 
rounds of screening were performed using 5 µl of phage end product.  
 
PCR amplification of recovered phage 
DNA recovered from immunoprecipitated and enriched phages was amplified 
individually, in replicate in a 50 µl PCR reaction using 1 µl phage, 1 U Q5 High-Fidelity 
DNA Polymerase, 1x Q5 DNA Polymerase Buffer, 200 µM dNTPs, 1 µM P1L primers and 1 
µM P1R primers using the thermocycler protocol in Table 2. 
Table 2  Thermocycler protocol for round one of PCR for sequencing preparation.  
Step Temperature (ºC) Time (mm:ss) 
1 96 00:30 
2 96 00:30 
3 52 00:30 
4 72 00:30 
5 (go to step 2) x3 
6 96 00:30 
7 96 00:30 
8 72 00:45 
9 (go to step 7) x20 
10 72 05:00 
11 4 ∞ 
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Amplicons from each PCR reaction were purified using MinElute (Qiagen) according 
to manufacturer’s recommendations and evaluated for length using a Bioanalyzer DNA 1000 
kit (Agilent) and quantified using a Qubit 2.0 fluorometer (Life Technologies). After diluting 
the end product from the first round of PCR to 50 pg/µl, a second round of PCR was 
performed using the same Q5 procedure as above but using 1 µl 50 pg/µl DNA amplicons 
instead of 1µl phage IP end products and a different thermocycler protocol (Table 3). Unique 
primer indices were incorporated into the reverse primers to differentiate the samples after 
sequencing (Table 4). 
Table 3  Thermocycler protocol for round two of PCR for sequencing preparation. 
Step Temperature (ºC) Time (mm:ss) 
1 96 00:30 
2 96 00:30 
3 50 00:30 
4 72 00:30 
5 (go to step 2) x3 
6 72 05:00 
7 96 00:30 
8 72 00:45 
9 (go to step 7) x10 
10 72 05:00 
11 4 ∞ 
 
DNA was again purified using MinElute (Qiagen), quantified using Qubit 2.0, and 
quality analyzed using a Bioanalyzer (Agilent). Using the electropherogram from the 
bioanalyzer, a ratio of target DNA to whole sample DNA was calculated and multiplied by 
the sample DNA concentration given by the Qubit 2.0 to identify the DNA concentration of 
the correctly sized amplicons. Equimolar amounts of target DNA from each replicate were 
combined (1.5 – 2.0 µg total DNA) and concentrated using MinElute kit (Qiagen). Two 
percent agarose gels (Sage Science) were used to remove oligonucleotides shorter than 360 
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bp or longer than 420 bp. The remaining DNA was then concentrated using a MinElute kit 
(Qiagen), quantified on a Quibit 2.0 fluorometer and submitted for sequencing.  
Table 4  Illumina sequencing primer indices and their corresponding samples.  
Animal ID Time Point Nextera Index Index Sequence 
401 D0 IP7-N701 TAA GGC GA 
 D30 IP7-N702 CGT ACT AG 
406 D0 IP7-N703 AGG CAG AA 
 D30 IP7-N704 TCC TGA GC 
413 D0 IP7-N705 GGA CTC CT 
 D30 IP7-N706 TAG GCA TG 
421 D0 IP7-N707 CTC TCT AC 
 D30 IP7-N708 CAG AGA GG 
423 D0 IP7-N709 GCT ACG CT 
 D30 IP7-N710 CGA GGC TG 
427 D0 IP7-N711 AAG AGG CA 
 D30 IP7-N712 GTA GAG GA 
 
Data Analysis 
Sequencing reads were binned according to their sample index. From each read, the 
first 44 bases were trimmed to remove the residual T7Select vector sequence and all bases 
were trimmed off the end leaving 108 bp sequences. To match that length, the 
oligonucleotides in the original library were truncated to 108 bp as well to allow for perfect 
alignment of sequence reads to the reference library. After truncating the reference library, 
some sequences were no longer unique and had 100% matches to other 108 bp sequences. 
Duplicates were removed and compiled into a list.  
The reference library of unique 108 bp oligonucleotides was formatted with bowtie2-
build to create a database for the alignment tool bowtie2. The sequencing reads were then 
aligned with the newly created database using bowtie2, and the number of reads per oligo 
were counted and compiled into a table for each sample. A full outer join was used to merge 
the individual count files for each sample into a single raw count table for the experiment. 
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This table is the input for the PhIP-Seq python program, phip. The first step of the phip 
program is to normalize the data using the function “normalized_counts” with “size-factors” 
being used as the method of normalization.  
After normalizing, peptide counts were log transformed before calculating means and 
standard errors for each peptide and time point of the five RB51 vaccinated cattle. A 
threshold of 1.0 on the log scale was used to filter out peptides with low counts, leaving a list 
of peptides with higher counts at Day 0 and/or Day 30. Peptides that had an increased mean 
count at Day 30 compared to Day 0 in at least three out of the five vaccinated cows were 
selected as potential candidates for diagnostic use, while those that had high counts in all 
samples and time points were compiled into a list of poor candidates.  
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CHAPTER 4.    RESULTS 
Library Design  
Of the 3153, 3161 and 3099 proteins from B. abortus, B. suis and B. melitensis, 
respectively, we removed 829, 898 and 888 proteins, respectively, from our oligopeptide 
library due to high sequence similarity to proteins from other bacterial genomes outside the 
library design parameters.  These reductions resulted in representation of approximately 72% 
of potential Brucella proteins within the oligonucleotide library. From the remaining 
proteins, 64,454 oligopeptides were designed with 28,670 duplicate oligos across Brucella 
species removed due to redundancy.  This resulted in our synthesized library containing a 
total of 35,784 unique oligonucleotide sequences. 
Table 5 Breakdown of proteins used in the library design for each Brucella species. 
Following removal of proteins due to similarities with other taxa outside of the Brucellaceae 
family and redundancy between species, a little over 70% of proteins are included in the 
library.   
Species # Proteins # Removed # Kept % Kept 
B. abortus 3,153 829 2324 73.7 
B. melitensis 3,099 888 2211 71.3 
B. suis 3,161 898 2263 71.6 
Total 9,413 2,615 6,798 72.2 
 
Oligopeptide Library Amplification and Phage Library Preparation/Quantification 
The synthesized oligos were PCR amplified and assessed for correct size via the 
Bioanalyzer. As shown in Figure 1, successful amplification of the oligo library can be 
observed as definitive bands are seen the expected amplicon size of 216 base pairs (bp).  
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Figure 1  Oligo library PCR gel. Lane 1 contains the 1 Kb Plus DNA Ladder (Invitrogen). 
The band in lane 2 is the 216 bp amplicons of the oligo library. 
From this amplified oligo library two phage libraries were generated in parallel. 
Initial titers suggested 1.695 x 107 and 1.765 x 107 pfu/ml, for library A and library B, 
respectively. As phage concentrations were too low to be used for IP, entire contents of both 
libraries were used for amplification in E. coli BLT5403, resulting in phage titers of 
approximately 5.3 x 1010 and 7.4 x 1010 pfu/ml, for library A and library B, respectively. 
Therefore, we were able to successfully increase phage library titers by 3 logs in each 
replicate. 
 
Oligopeptide Representation within Phage Libraries 
The two phage libraries were sequenced after amplification in E. coli BLT5403 to 
assess the representation of oligopeptides in each library. After one round of PCR to generate 
amplicons for sequencing preparation, all replicates from library A had one clear band at the 
desired size of 354 bp (Figure 2, red box), whereas all replicates of library B showed a 
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double band near 354 bp separated by around 10 bp (Figure 2, green box). A second round of 
PCR was performed for sequencing preparation, and the same double bands were present in 
the library B replicates at the expected amplicon length of 410 bp (Figure 3). Library A 
replicates had just one band again. The four replicates for each library were pooled, run 
through a Pippin Prep gel to exclude DNA shorter than 360 bp and longer than 420 bp, and 
sequenced on an Illumina Miseq platform.  
 
Figure 2  Assessment of the first round of PCR amplicons to prepare the phage libraries 
for sequencing. Shown are the PCR product from the first round of PCR amplification of 
library A (red box, lanes 2-5) and library B (green box, lanes 6-9) around the expected 
amplicon length of 354 bp.  
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Figure 3  Assessment of the second round of PCR amplicons to prepare the phage libraries 
for sequencing. The expected amplicon length is 410 bp. The colored boxes are labeled the 
same as Figure 2. 
 
Sequencing data indicated that greater that 99% of the total oligos were identified in 
both libraries (Table 6).  Analysis showed that there was some variability between the two 
libraries in terms of the number of read counts per individual oligopeptide. In library A, the 
greatest number of counts of an individual oligopeptide was 3,503, while in library B we 
observed a dramatic skewing, with 1,723,216 counts for one individual oligopeptide (Figure 
4). Further analysis indicated that the most abundant oligo in library B represented over 14% 
of total reads, whereas ideally each of the 35,784 designed oligopeptides would be 
represented by 0.0028% of total reads. However, in library A, the distribution of read counts 
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per oligo was more normal compared to library B, which was heavily skewed towards a 
single oligo outlier. Since library A demonstrated a more even distribution of oligopeptides, 
it was chosen for use in the immunoprecipitation screening.  
Table 6  Quantitative summary of the sequencing data from the two phage libraries. 
Indicated are the total number of reads obtained, the number of oligos found and the 
percentage of oligo coverage based on the 35,784 oligo total in our library design. 
Sample # Reads Oligos Found % Oligo Coverage 
Phage Library A 9,545,179 35,709 99.79 
Phage Library B 11,931,767 35,694 99.75 
Combined 21,476,946 35,733 99.86 
 
 
Figure 4  Distribution of sequencing read counts per oligo (log10) for each library 
replicate. 
 
Assessment of anti-RB51 titers in bovine sera 
Anti-RB51 IgG responses peaked between 30 and 60 days post-RB51 vaccination, 
with a slow decline the remaining time points analyzed (Figure 5).  Because of the higher 
levels of anti-RB51 IgG on day 30 after vaccination as compared to levels prior to 
vaccination, samples from six cattle at this sampling time were chosen for library screening.   
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Figure 5  Assessment of RB51-specific IgG titers in serum of RB51-vaccinated animals.  
Time course showing the levels of anti-RB51 IgG in serum prior to and post-RB51 
vaccination. IgG levels appear to peak between 4- and 8-weeks post-vaccination, and show a 
steady decline over time.  
 
Screening of Phage Library with Sera 
Following screening of the phage library via immunoprecipitation with anti-RB51 
sera from five animals, isolated DNA was amplified twice by PCR and quantified on a 
fluorometer and bioanalyzer. Three samples at 30 days post vaccination, two for steer 401 
and 1 from steer 423 failed to amplify such that DNA could not be detected via bioanalyzer 
and fluorometer after the first PCR amplification. However, after the second round of 
amplification, DNA was detected for each of those samples.  When analyzed by bioanalyzer 
(Fig 6 and 7) 2 of 3 samples for which DNA was not detected do not have a band at the 
expected amplicon size of 354 bp, however, remaining samples do.  After the second PCR 
amplification, all samples demonstrate a clear band at the expected amplicon size of 410 bp.  
However, DNA was also detected via fluorometer in the negative control samples which 
suggest that either phage or DNA from other samples contaminated the negative controls. 
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Figure 6  Bioanalyzer gel image of the first round PCR amplicons after IP. Expected 
amplicon size is 354 bp. Shown here are samples 1 – 12 of 48 total samples and the negative 
control (no phage template). 
 
Figure 7  Bioanalyzer gel image of the second round PCR amplicons after IP. Expected 
amplicon size is 410 bp.  
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Data from the bioanalyzer and fluorometer were used to combine equimolar 
concentration of target DNA (410 bp) from each sample for sequencing.  The 
electropherogram graph from the bioanalyzer allows us to quantify the DNA of different 
lengths in a given sample (Figure 8). The target DNA length of 410 bp is highlighted by the 
peaks between the vertical blue lines, and the whole sample DNA is highlighted between the 
green lines. Peaks 1 & 8 are size markers from the bioanalyzer kit and therefore are not part 
of the whole sample DNA. The bioanalyzer calculates the area under each peak and adds 
them together for each highlighted region (Table 7). A ratio of the target area to whole 
sample area was calculated and multiplied by the Qubit DNA concentration to estimate the 
actual concentration of DNA of the expected length in each sample. With that data, 
equimolar concentrations of DNA can be combined from all samples to make one single 
sample for amplicon size exclusion (Pippin Prep) and sequencing.  
 
Figure 8  Bioanalyzer electropherogram of sample 1. The x-axis represents the amplicon 
length in base pairs, and the y-axis represents the abundance of amplicons of a given length 
(fluorescence units). Regions were selected to highlight the ratio of target DNA of the 
expected size to total DNA of the sample. The target region (blue lines) flanks the peak 
around 410 bp while the total sample region (green lines) spans the entire area between the 
upper and lower markers of the bioanalyzer assay (peaks 8 and 1, respectively).   
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Table 7  Target DNA concentration calculations. Only four samples are shown here along 
with total sample DNA concentrations measured by the Qubit fluorometer, target region 
areas from the bioanalyzer electropherogram, sample region areas, a target/sample area 
ratio, and the adjusted DNA concentration. Whole sample DNA concentrations are listed in 
the second column. The Target / Sample column lists the ratio of the highlighted regions from 
the bioanalyzer electropherogram. The Adjust Concentration column is the product of the 
Qubit DNA concentrations and the Target / Sample ratio.  
Sample 
ID 
Qubit [DNA] 
(ng/µl) 
Target 
Area 
Sample 
Area 
Target /  Sample 
Ratio 
Adjusted [DNA]  
(ng/µl) 
1 39.6 767.3 1144.5 0.67 27 
2 36.0 744.8 1019.9 0.73 26 
3 35.4 949.4 1268.2 0.75 27 
4 38.4 761.7 1061 0.72 28 
 
Protein targets from phage library screening 
Forty seven antigenic peptides were identified by our analysis (Table 8). These 
peptides had an increased antibody response at Day 30 compared to Day 0 in at least three 
out of the five RB51 vaccinated cattle serum samples. Conversely, fourteen peptides showed 
high responses across all samples and time points (Table 9). 
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Table 8  Antigenic peptides that had an increased response at day 30 in at least 3 of the 5 vaccinated steers.  
Accession # Segment Protein Mean 
Day 0 
SEM Mean 
Day 30 
SEM 
AIJ87770 9 periplasmic binding family protein 0.00 0.00 1.27 0.56 
AIJ87874 12 amidohydrolase family protein 1.92 0.78 2.26 0.49 
AIJ88154 12 binding--dependent transport system inner 
membrane component family protein 
1.03 0.84 1.04 0.53 
AIJ88432 5 HAMP domain protein 0.32 0.32 1.06 0.68 
AIJ88831 4 extensin-like family protein 0.12 0.12 1.41 0.85 
AIJ88988 12 tol-pal system protein YbgF 2.05 0.88 1.90 0.78 
AIJ89006 3 serine O-acetyltransferase 1.61 0.70 2.30 0.54 
AIJ89367 5 EF-hand domain pair family protein 0.62 0.38 1.68 0.70 
AIJ89526 4 hypothetical protein DK63_995 0.34 0.10 1.53 0.86 
AIJ90259 1 L,D-transpeptidase catalytic domain protein 0.69 0.42 1.21 0.60 
CAJ10022 28 Immunoglobulin/major histocompatibility 
complex:Phosphoesterase PHP, N-terminal:DNA 
polymerase III alpha subunit 
1.32 0.82 2.44 0.54 
CAJ10039 23 Protein of unknown function DUF214 0.93 0.74 1.72 0.88 
CAJ10044 7 conserved hypothetical protein 1.00 0.40 1.17 0.14 
CAJ10060 6 Prokaryotic sulfate-/thiosulfate-binding 
protein:Bacterial extracellular solute-binding 
protein, family 1 
1.82 0.59 2.22 0.57 
CAJ10146 2 Bacterial regulatory protein, LuxR 
family:Autoinducer binding domain 
0.79 0.49 1.32 0.67 
CAJ10263 3 Acriflavin resistance protein 0.59 0.59 1.30 0.90 
CAJ10285 2 Pollen allergen Poa pIX/Phl pVI, C-terminal 2.78 0.74 2.86 0.55 
CAJ10615 5 ATP/GTP-binding site motif A (P-loop):Porin, alpha 
proteobacteria type 
0.30 0.30 1.46 0.62 
CAJ10922 30 Aminoacyl-tRNA synthetase, class I:Aminoacyl-
tRNA synthetase, class Ia:Valyl-tRNA synthetase 
0.04 0.12 1.05 0.82 
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Table 8 (continued) 
CAJ11024 4 Universal stress protein (Usp) 0.00 0.00 1.33 0.67 
CAJ11132 14 Bacterial surface antigen (D15) 0.00 0.00 1.45 0.61 
CAJ11351 8 Endonuclease/exonuclease/phosphatase family 0.80 0.58 1.04 0.90 
CAJ11432 3 Esterase/lipase/thioesterase, active site:Prolyl 
aminopeptidase S33 
0.00 0.00 2.15 0.55 
CAJ11504 2 lipoprotein, putative 1.18 0.80 1.91 0.30 
CAJ11632 9 unnamed protein product 0.82 0.45 1.35 0.61 
CAJ11737 35 DEAD/DEAH box helicase:Helicase, C-
terminal:ATP/GTP-binding site motif A (P-
loop):Aldehyde dehydrogenase 
0.59 0.37 1.47 0.86 
CAJ11923 3 Universal stress protein (Usp):Usp domain 0.68 0.41 1.52 0.75 
CAJ11994 12 Antifreeze protein, type I:Peptidase M20/M25/M40 1.18 0.80 1.39 0.81 
CAJ12013 4 ATP/GTP-binding site motif A (P-loop):ABC 
transporter:AAA ATPase 
0.85 0.52 1.47 0.66 
CAJ12174 14 ATP/GTP-binding site motif A (P-loop):ABC 
transporter:AAA ATPase 
1.10 0.40 1.62 0.46 
CAJ12175 End Adenine nucleotide translocator 1:Basic membrane 
lipoprotein 
0.00 0.00 1.21 0.80 
CAJ12180 End Eubacterial/plasma membrane H+-transporting two-
sector ATPase, C subunit:AMP-dependent 
synthetase and ligase 
1.03 0.48 1.45 0.54 
CAJ12361 3 conserved hypothetical protein 1.30 0.58 1.77 0.54 
CAJ12364 12 High mobility group proteins HMG-I and HMG-
Y:Pseudouridine synthase, Rsu:RNA-binding 
S4:Pseudouridine synthase 
0.42 0.25 1.06 0.43 
CAJ12458 2 sugar transporter 0.12 0.07 1.17 0.88 
CAJ12472 5 Imidazolonepropionase:Amidohydrolase 1.48 0.78 2.90 0.55 
CAJ12573 4 conserved hypothetical protein 0.10 0.13 1.45 0.77 
CAJ12760 2 Fumarate lyase:Delta crystallin 0.41 0.41 1.54 0.66 
CAJ12866 8 Bacterial extracellular solute-binding protein, family 
5 
0.62 0.40 1.03 0.57 
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Table 8 (continued) 
CAJ13029 1 Glutaminase 0.72 0.72 1.26 0.47 
CAJ13152 12 60 kDa inner membrane protein 1.02 0.86 2.04 0.64 
CAJ13269 8 OmpA/MotB domain 0.00 0.00 1.11 0.68 
KFJ31611 17 hypothetical protein DK68_981 1.01 0.62 2.18 0.52 
KFJ32133 15 outer membrane autotransporter barrel domain 
protein 
0.91 0.57 1.92 0.62 
KFJ32373 11 glycosyl hydrolases 25 family protein 2.28 0.59 1.43 0.70 
KFJ32793 11 ureD urease accessory family protein 0.74 0.34 1.62 0.58 
KFJ32807 3 hypothetical protein DK68_1028 1.46 0.63 2.08 0.55 
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Table 9 Antigenic peptides that triggered a humoral response in all samples and time points. These are peptides to avoid for use in 
diagnostics, because they showed high antigenicity regardless of vaccination status. 
Accession # Segment Protein Mean Day 0 SEM Mean Day 30 SEM 
AIJ88226 2 esterase-like activity of phytase 
family protein 
2.44 0.79 2.41 0.83 
AIJ88689 10 asparaginase family protein 1.14 0.36 1.12 0.13 
AIJ89003 2 hypothetical protein DK63_460 1.34 0.23 1.97 0.48 
CAJ10066 1 Phenazine biosynthesis 
PhzC/PhzF protein 
2.34 0.82 2.30 0.89 
CAJ10386 End TPR repeat 3.03 0.72 2.93 0.78 
CAJ10419 5 Cell division protein FtsJ:RNA-
binding S4:Hemolysin A 
0.98 0.35 2.33 0.88 
CAJ10680 7 Ribonuclease T2 2.14 0.76 2.22 0.49 
CAJ10922 1 Aminoacyl-tRNA synthetase, 
class I:Aminoacyl-tRNA 
synthetase, class Ia:Valyl-tRNA 
synthetase, class Ia 
2.25 0.37 2.36 0.45 
CAJ11309 11 CBS domain:Transporter 
associated domain:Integral 
membrane protein TerC family 
2.07 0.85 2.32 0.82 
CAJ11323 11 TonB-dependent receptor 
protein 
1.35 0.36 2.00 0.89 
CAJ12189 6 Leu/Ile/Val-binding protein 
family 
2.14 0.48 2.41 0.45 
CAJ12679 5 Glycine cleavage T protein 
(aminomethyl transferase) 
1.98 0.95 1.90 0.74 
KFJ32022 12 tol-pal system protein YbgF 2.88 0.80 3.14 0.77 
KFJ32133 48 outer membrane autotransporter 
barrel domain protein 
0.84 0.18 1.26 0.14 
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CHAPTER 5.    DISCUSSION 
The work presented here demonstrates the successful application of the phage 
immunoprecipitation sequencing (PhIP-Seq) for the discovery of antigenic Brucella peptides 
using bovine serum samples.  To accomplish this, we first generated a synthetic 
representation of the Brucella peptidome encompassing 3 species, B. melitensis, B. abortus 
and B. suis, for display onto a phage T7 phage library. The PhIP-Seq methodology, as 
initially published by Larman et al., has been successfully used to perform all-inclusive 
analysis of antibodies and antigens involved in a variety of disease processes. To our 
knowledge, this is the first report of this technique being utilized to interrogate the Brucella 
proteome for antigenic targets to RB51-specific antibodies.   
Secondly, we successfully expressed our library in phage such that >35,000 linear 
peptides from open reading frames of B. abortus, B. melitensis and B. suis were available for 
antibody-based screening. Quality control measures determined that we were able to 
sequence and positively identify greater than 99.7% of the peptides included in our designed 
library. Additional quality control steps demonstrated that we had relatively even distribution 
of each peptide within our expressed library. In the library chosen for screening, 97.6% of the 
individual oligonucleotides in the amplified library were between 10% and 1000% of the 
average oligonucleotide count (average of 339 reads/oligonucleotide, range of 97.6% of 
library between 34 to 3390 reads).  
Another achievement was completion of the immunologic screening of the phage 
library with cattle sera. The PCR amplification of the enriched phage stock after screening 
demonstrated that a number of specific oligonucleotides resulted in enrichment and increased 
representation.  One measure of repeatability was to assess if oligos with mean counts of 
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great than 1 log at Day 0 also a mean counts of greater than 1 log at day 30.  By this criteria, 
this analysis of repeatability indicated that 52 of 82 oligonucleotides (63%) had mean counts 
above 1 log at Day 30 when the Day 0 mean count was above 1 log.  In comparison, 50 
oligonucleotide sequences were found to have mean counts above 1 log at Day 30 that also 
demonstrated an increase of at least 0.5 log from mean count at Day 0.  Assuming that these 
sequences represent linear peptide fragments of interest, these oligonucleotides represented 
approximately 0.14% of the library (50 out of 35,784 oligonucleotides). Our data 
demonstrated that immunogenicity of specific oligonucleotides to repeat between Day 0 and 
Day 30, and that specific peptide sequences appear to give greater responses in vaccinates at 
Day 30.  Overall, this suggests that the data pattern is not random and that technique has 
value in screening for antigenic peptides.  
We identified 47 peptides that might be candidates for further analysis as antigens for 
use in brucellosis diagnostic tests. Although most have not been previously identified, one of 
the peptides, protein CAJ10060 – an extracellular sulfate-/thiosulfate- binding protein, has 
been previously shown to be antigenic in naturally infected cattle and sheep (Wareth et al., 
2016). In a similar manner, one study identified aldehyde dehydrogenase as antigenic during 
immunoproteomic screening of B. abortus (Kim et al., 2014).  Another identified protein, 
amidohydrolase, is in the same protein family as urease, a known immunogenic protein of 
Brucella (Abkar et al., 2015).  Other identified proteins, such as serine O-acetyltransferase, 
glutaminase, and LuxR are interesting in that they may play important functions for Brucella 
survival and persistence under in vivo conditions (Mirabella et al., 2012; Kumar et al., 2014; 
Freddi et al., 2017)  Another protein, a tRNA synthetase, is similar to methionyl-tRNA-
synthetase a protein that has been identified as a potential drug target for brucellosis (Ojo et 
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al., 2016) Other proteins from previous publications were identified by mean counts greater 
than 0 in our data but did meet the criteria we set for further analysis.  Overall, these data 
demonstrate a benefit of the PhIP-Seq technique and supports further screening of serum 
samples from infected animals.  
Several peptides were also found to have high antigenicity across all animals and time 
points regardless of vaccination status. Since mean counts to these proteins were high at Day 
0, responses to these peptides most likely are demonstrating cross reactivity to proteins from 
other common bacterial symbionts of cattle. This makes these peptides poor candidates for 
further diagnostic evaluation. 
In further work, additional replicates of RB51 vaccinates will need to be added to 
allow detection of statistical differences.  This should include additional animals at the time 
point used in the current study, in addition to comparing responses to our PhIP library at later 
time points after vaccination.  Data has previously indicated that cattle vaccinated with B. 
abortus strain 19 may develop greater humoral responses to protein antigens of RB51 at 
approximately 12 to 16 weeks after vaccination as compared to responses at 4 to 8 weeks (S. 
Olsen, unpublished).  This may suggest that maturation of the antibody response after strain 
19 vaccination may be increasingly focused on protein antigens as compared to antigenic 
components of the lipopolysaccharide.   In addition to further evaluation in RB51 or strain 
19-vaccinated cattle, screening should be completed on cattle infected with B. suis, swine 
infected with B. suis, and small ruminants infected with B. melitensis.  Screening of these 
hosts may identify differences in antibody responses between the hosts or between Brucella 
species (in hosts commonly infected with multiple Brucella species).  This would be of great 
value for regulatory personnel as it may allow development of a diagnostic to determine the 
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species of Brucella causing infection.  Also, due to the high homology between Brucella 
species, it is reasonable to predict that many protein epitopes recognized by antibody 
responses may be conserved across host/Brucella species combinations.   
Further work should also express the identified protein targets as recombinant 
proteins and screen them individually using an ELISA, or another antibody based test, to 
evaluate the repeatability of the preliminary data that was generated in the current study. 
In conclusion, this work developed a PhIP-Seq library for B. abortus, B. suis, and B. 
melitensis, expressed the library in phage, and successfully screened the library with sera 
from cattle vaccinated with B. abortus strain RB51.  The screening identified new targets for 
development into novel diagnostic tests that may be useful in current regulatory programs.   
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